Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Icon ( (ICLR) ) just unveiled an update.
On August 12, 2025, ICON plc announced that a large-scale next-generation COVID vaccine study, which had been actively enrolling participants, received a stop work notice from BARDA, leading to a halt in new subject screening and dosing. Despite this setback, which will affect revenue in the second half of 2025, ICON maintains its full-year financial guidance, reflecting ongoing discussions with BARDA and continued follow-up with already enrolled participants.
The most recent analyst rating on (ICLR) stock is a Buy with a $380.00 price target. To see the full list of analyst forecasts on Icon stock, see the ICLR Stock Forecast page.
Spark’s Take on ICLR Stock
According to Spark, TipRanks’ AI Analyst, ICLR is a Outperform.
Icon’s overall stock score reflects strong financial performance and reasonable valuation. Technical indicators present mixed signals, with short-term weakness but medium-term support. The balanced sentiment from the earnings call, despite being excluded from the weighted calculation, suggests a stable outlook.
To see Spark’s full report on ICLR stock, click here.
More about Icon
ICON plc operates in the healthcare and pharmaceutical industry, providing clinical research services. The company focuses on offering comprehensive solutions for drug development and clinical trials, positioning itself as a key player in advancing medical research and innovation.
Average Trading Volume: 1,392,662
Technical Sentiment Signal: Sell
Current Market Cap: $12.42B
For a thorough assessment of ICLR stock, go to TipRanks’ Stock Analysis page.